MDGL

Madrigal Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 7/10
  • Momentum↑ 5/10
Madrigal Pharmaceuticals sales and earnings growth
MDGL Growth
Good
  • Revenue Y/Y↑ 432.05%
  • EPS Y/Y↑ 41.32%
  • FCF Y/Y↑ 58.22%
Madrigal Pharmaceuticals gross and profit margin trends
MDGL Profitability
Neutral
  • Gross margin ↑ 94.10%
  • EPS margin↓ -30.10%
  • ROIC↓ -29.60%
Madrigal Pharmaceuticals net debt vs free cash flow
MDGL Risk
Great
  • Debt / Equity↓ 0.6
  • Debt / FCF↓ 0.7
  • Interest coverage↓ -11.9

Madrigal Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗